Even though MGMT promoter methylation in CpG rich sequences and subsequent overexpression is well known for mediating temozolomide resistance in glioblastoma, the clinical relevance of targeting MGMT in MB has only recently emerged (82). Here, MGMT is linked to glioblastoma.